Pricing forensics · from the 250-topic plan
The two-vial month: what dose changes do to vials, bills, and the meaning of “monthly”
Titration means your milligrams climb — but your vial doesn't grow with them, and how a program reconciles that gap is a pricing model wearing a lab coat. Three architectures exist in the wild: fixed-mg vials (a dose step makes the “month” empty in three weeks — the depletion tax), dose-sized vials (a mid-cycle step strands the remainder — the waste tax), and dose-proof monthly pricing (the program absorbs the ladder — the problem, priced away). This piece works the math of each, shows how tiered programs can charge the step-up tax and the depletion tax on the same climb, and ends with the three questions that reveal any program's architecture before you're inside it.
The gap nobody prices out loud
A “monthly” vial is really a quantity of milligrams; a month is really four (and a third) doses at whatever rung you're on. At 2.5 mg weekly a vial holding 10 mg is a month; step to 5 mg and the identical vial is a fortnight. The ladder guarantees this collision happens repeatedly in year one — so every program has already decided who pays for it. The decision just isn't on the pricing page.
Architecture one: the depletion tax
Fixed-mg shipping — a set total of medicine per billing cycle — keeps the label honest and the calendar slippery: each rung up shortens the “month.” Worked: a patient billed monthly for a fixed quantity sized to 2.5 mg who titrates on schedule will find billing cycles and medicine cycles diverging by mid-ladder — reordering early, effectively paying more per month at exactly the doses where tiered programs also raise rates. The tell on the page: prices quoted per vial or per mg-total rather than per month of therapy at your dose.
Architecture two: the waste tax
Dose-sized shipping matches each vial to your current prescription — cleaner calendars, new failure mode: the mid-cycle change. A clinician step (up, down, or a hold) leaves a part-used vial whose remainder is either re-mathed at the old concentration (workable; error-inviting), returned (rarely — sterile product doesn't come back), or discarded — the discount refunded as waste. The clause to find before paying: what happens to a partially used vial when my dose changes? Programs with an answer wrote the policy; programs without one wrote it too, just in your ink.
The double charge, assembled
Now stack the architectures the way the tier market does: a program with dose-tiered rates and fixed-mg fulfillment charges the climb twice — the tier rate rises with your rung (the step-up tax, ~$80–$100/month in on-record corridors) while the fixed quantity depletes faster (the depletion tax, an unpriced surcharge on the same rung). Neither line item is dishonest alone; together they mean the advertised monthly price is only true at the door dose, which is the one dose everyone leaves. This is the quiet mechanics under every annualization this site runs.
Architecture three: the dose-proof answer
The third model simply deletes the variable: one monthly price at any rung, medication supplied to the prescribed dose — the ladder becomes the program's logistics problem instead of your billing surprise. The audited benchmark runs exactly this architecture ($139 tirzepatide / $119 semaglutide at every dose, verified 24-for-24), which is why its “monthly” survives titration with its meaning intact — and why this article's forensics double as its shopping conclusion: the only “monthly price” worth comparing is one that stays true at 10 mg. The dose-proof month ↗
The three questions
In writing, before enrolling: “Is my price per month of therapy at my prescribed dose, or per vial/mg quantity?” “If my dose increases mid-cycle, what do I pay and what happens to the current vial?” “At 10 mg (or 2.4 mg), what exactly arrives each month and what exactly am I billed?” The answers sort every program into one of the three architectures above — and the architecture, not the door price, is what you'll be living with by spring.
FAQ
Why did my monthly GLP-1 vial stop lasting a month?
Because it was a milligram quantity, not a month: dose increases deplete fixed-mg vials faster — the unpriced depletion tax of titration under per-vial billing.
What happens to a partially used vial when my dose changes?
Whatever the program's written policy says — re-use at old concentration, or discard; sterile product rarely returns. Get the clause before it's your problem.
What billing model avoids titration surprises?
Dose-proof monthly pricing — one rate at any rung with medication supplied to the prescribed dose — which is the audited benchmark's architecture and the only “monthly” that stays true up the ladder.
Sources
- On-record fulfillment and tier structures across the field — the open dataset.
- Label titration schedules — the collision generator.
- Audited dose-proof pricing, verified 2026-08-14.